{"entity":{"id":"idea-reg-combination-price-attribution","kind":"idea","name":"A combination pricing rule so two-drug regimens are not priced as two monopolies","aka":[],"tldr":"When two expensive cancer drugs are combined, the price is often the sum of both even though the extra benefit is smaller. A rule for splitting the total value between them is needed.","summary":"Combination regimens (checkpoint inhibitor plus targeted agent, ADC plus immunotherapy) frequently fail cost-effectiveness thresholds because each manufacturer prices for the full value, and competition law is cited as blocking joint negotiation. The UK's 2023 ABPI-NICE combination framework allows a backbone manufacturer to offer a rebate when its drug is used as part of a combination. The proposal is to generalise this: payers set a total price ceiling for the regimen based on its incremental benefit, a published attribution rule splits it between components, and competition authorities issue safe-harbour guidance for the resulting arrangements.","asOf":"2026-09-08","links":[{"label":"NICE combination treatments framework (page moved; nearest live section)","url":"https://www.nice.org.uk/about/what-we-do/our-programmes/nice-guidance/nice-technology-appraisal-guidance/"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":["b-drug-pricing","b-combination-space"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hypothesis":"Under the framework, the proportion of combination regimens recommended by HTA bodies rises by at least a third, and total regimen prices fall relative to the sum of monotherapy prices.","rationale":"The best new regimens are increasingly combinations of drugs from different companies; without an attribution mechanism, patients lose access to the most effective treatments because of a pricing coordination failure rather than any scientific limitation.","test":"Evaluate uptake and prices of combinations assessed under the UK framework over three years; adopt the framework in two other payers with competition-authority guidance and compare recommendation rates.","maturity":"early-clinical","actor":"payer","cost":"small","horizonYears":3},"route":"/ideas/idea-reg-combination-price-attribution/","neighbours":{"bottleneck":[{"id":"b-drug-pricing","kind":"bottleneck","name":"Prices and value","route":"/bottlenecks/b-drug-pricing/"},{"id":"b-combination-space","kind":"bottleneck","name":"Too many combinations to test","route":"/bottlenecks/b-combination-space/"}]}}